Back to Overview
Dr. Martin Fabry
Martin Fabry completed his bachelor’s degree in Molecular Biomedicine at the University of Bonn in 2014 and subsequently moved to the US as a visiting scientist at Cold Spring Harbor Laboratory (New York), where he worked on improving CRISPR/Cas9 technologies. In 2016, he obtained a master’s degree in Life and Medical Sciences with a focus on molecular mechanisms of immunity, before starting his PhD in Medical Sciences with Cancer Research UK at the University of Cambridge, where he studied genome organisation and stability.
After receiving his doctorate in 2020, Martin worked as a postdoctoral fellow in computational biology at the Gurdon Institute and the European Bioinformatics Institute (EBI) in Cambridge, focusing on stem cell development and the establishment of new technologies for stem cell differentiation.
Martin is a registered German and European Patent and Trademark Attorney, and became Managing Director of IP2 in early 2025.
- Life Science 100%
What more there is to say...
In his leisure time Martin likes running, hiking, diving and rowing.
What moves me
Nagoya Protocol 2.0
Additional New White Paper from IP2 concerning the Nagoya Protocol Our white paper "10 years of the Nagoya Protocol" from late 2023 explains the background, summarizes the current implementation into national law and provides an overview of the requirements that...
Penalty for the free-kick spray
In 2013, international soccer was enriched by a special curiosity: referees suddenly sprayed lines on the pitch with a kind of shaving foam to determine the correct distance of the kicker at a free kick. FIFA is said to have once promised Heine Vilarinho-Diaz (1), the...
EPO’s start-up offensive – not a big hit
It is a truism that newly founded, highly innovative companies are particularly dependent on the protection of their intellectual property, but often lack the budget to ensure this in a comprehensive manner. This is doubly fatal, as IP is usually the only asset that...
Back to Overview